ResearcherColumbia UniversityActive in the last 2 years
Linda Y. Wu
Matched on ORCID iD 0000-0002-5818-7678; OpenAlex author ID A5063707610, A5152537329. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2026: 3 papers
Papers 3
- Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Co-author DOI 10.1038/s41467-026-76559-4↗
- Current landscape of RAS-targeted therapy for pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag379↗
- Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO. Co-author DOI 10.1200/po-26-00138↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Gulam Abbas Manji · 3 shared papers, 2026 · strength 0.89
- Paper Current landscape of RAS-targeted therapy for pancreatic cancer. DOI 10.1093/oncolo/oyag379↗
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Alina Cornelia Iuga · 2 shared papers, 2026 · strength 0.39
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Michael S. May · 2 shared papers, 2026 · strength 0.39
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Alexander Grenander Raufi · 2 shared papers, 2026 · strength 0.39
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Susan Elaine Bates · 2 shared papers, 2026 · strength 0.39
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Benjamin Izar · 2 shared papers, 2026 · strength 0.39
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Kenneth P. Olive · 2 shared papers, 2026 · strength 0.39
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Emanuel F. Petricoin · 1 shared paper, 2026 · strength 0.20
- Brian William Labadie · 1 shared paper, 2026 · strength 0.20
- Andrea Califano · 1 shared paper, 2026 · strength 0.20
- Urszula N. Wasko · 1 shared paper, 2026 · strength 0.20
- Howard P. Safran · 1 shared paper, 2026 · strength 0.20
- Li Li · 1 shared paper, 2026 · strength 0.19
- Michael D. Kluger · 1 shared paper, 2026 · strength 0.19
- Beth Schrope · 1 shared paper, 2026 · strength 0.19
- John A. Chabot · 1 shared paper, 2026 · strength 0.19
- Tito Fojo · 1 shared paper, 2026 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.